Correction

Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T: Effects of Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol 14: 28–39, 2019, https://doi.org/10.2215/CJN.02510218.

Because of author error, a correction has been issued for the above referenced article.

In Table 2, the mean CRP (SD) values for DIALOGUE 4 currently read 0.8 (1.4) and 0.7 (1.1) for molidustat and epoetin, respectively. These values should be 7.9 (13.5) and 7.1 (11.1), respectively.

In Supplemental Table 4, the mean CRP (SD) values for DIALOGUE 4 currently read 0.9 (1.7), 0.6 (0.8), 0.8 (1.2), 0.8 (1.7), 0.8 (1.4), 0.7 (1.1), and 0.8 (1.3) for molidustat 25 mg, 50 mg, 75 mg, 150 mg, combined, control group, and total, respectively. These values should be 9.4 (16.6), 6.1 (8.4), 8.2 (11.8), 7.5 (16.7), 7.9 (13.5), 7.1 (11.1), and 7.7 (13.0), respectively.